WJA
DGX icon

Willis Johnson & Associates’s Quest Diagnostics DGX Stock Holding History

Willis Johnson & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$237K Buy
1,208
+8
+0.7% +$1.55K 0.01% 173
2025
Q4 		$208K Buy
1,200
+7
+0.6% +$1.27K 0.01% 173
2025
Q3 		$227K Buy
+1,193
New +$212K 0.01% 165

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Willis Johnson & Associates's DGX Position: Q1 2026 in Review

Willis Johnson & Associates increased its Quest Diagnostics (DGX) stake by 0.67% in Q1 2026, buying an estimated $1.55K and bringing the position to 1,208 shares worth $237K. The position accounts for 0.01% of the portfolio, ranked #173.

Willis Johnson & Associates first reported a position in DGX in Q3 2025 and has held it in 3 quarters since. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Willis Johnson & Associates held 1,208 shares of Quest Diagnostics worth $237K as of Q1 2026.
  • Willis Johnson & Associates bought 8 Quest Diagnostics shares in Q1 2026, an estimated $1.55K.
  • Quest Diagnostics made up 0.01% of Willis Johnson & Associates's portfolio in Q1 2026, its #173 holding.
  • Willis Johnson & Associates first reported a position in Quest Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Willis Johnson & Associates's 13F filing for Q1 2026, filed 23 Apr 2026.